The 5th Computational Drug Discovery & Development (CDD) for Biologics Summit

Built with insights from the likes of AbbVie, Sanofi, Amgen and Takeda; CDD for Biologics Summit has been specifically designed to help biopharma companies define strategies to further adapt computational tools, mitigate data availability issues and address computational-experimental challenges to add immediate value to their biologics pipelines.

This dedicated platform will enable you to address key challenges such as those of widespread data sharing, the experimental constraints of generating enough data and the importance of overcoming data silo-ing with organizations, as well as exploring new opportunities including a novel, AI-derived approach, an automated high-throughput engineering platform, successfully deploying ML algorithms and more.

Across 3 days online, 24 experts will share in-depth their findings on:

• Leveraging machine learning and computational programs to discover, design and develop de novo antibodies
• Model and design structure-based antibody and T cell receptor recognition
• Computational design of antibodies against spike epitopes of SARS-CoV-2
• Plug and play application and advantages of computational design
• Deep dives into computational modeling of immunogenicity prediction, validation; and opportunities for data availability and sharing

Join a diverse faculty of experts this October for the 5th annual gathering to uncover progress made, and how we can accelerate the adoption of computational tools in the discovery and development of biologics.

To know more about CDD for Biologics Summit please click here.